Global medicine spending will reach nearly $1.5 trillion by 2021 on an invoice price basis, up nearly $370 billion from the 2016 estimated spending level, says a newly released QuintilesIMS Institute report.
The Outlook for Global Medicines through 2021 predicts that growth will be driven primarily by newer medicines in developed markets and increased volume in pharmerging markets.
According to the report, the number of new medicines reaching patients will be historically large, addressing significant unmet needs in cancer, autoimmune diseases, diseases of the metabolism, nervous system disorders and others. There are 2,240 drugs in the late-stage pipeline and 45 new active substances expected to be launched on average per year through 2021, addressing significant unmet needs.
Read the summary and request the report